ID   HepG2-CYP3A22
AC   CVCL_E8Z3
RX   CelloPub=CLPUB00804;
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; HGNC:7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Genetic integration: Method=Transfection; Gene=UniProtKB; P00552; Klebsiella pneumoniae transposon Tn5 neo.
CC   Genetic integration: Method=Transfection; Gene=VGNC; VGNC:103554; Pig CYP3A22.
CC   Derived from site: In situ; Liver; UBERON=UBERON_0002107.
DI   NCIt; C3728; Hepatoblastoma
DI   ORDO; Orphanet_449; Hepatoblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0027 ! Hep-G2
SX   Male
AG   15Y
CA   Cancer cell line
DT   Created: 14-08-25; Last updated: 14-08-25; Version: 1
//
RX   CelloPub=CLPUB00804;
RA   Xue, Zheng-Kai
RA   Wei, Hong
RA   Shang, Hai-Tao
RA   Yang, Gen-Qing
RA   Ye, Bin
RT   "Establishment of a HepG2 cell line stably expressing CYP3A22 and
RT   identification of the metabolic activity of the probe drugs.";
RL   Di 3 Jun Yi Da Xue Xue Bao 31:1552-1555(2009).
//